Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Commentary

Nature Clinical Practice Oncology

Volumn 5, Issue 12, 2008, Pages 696-697

  Hodi, F Stephen ^a   Fisher, David E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; NY ESO 1 ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; MELANOMA; METASTASIS POTENTIAL; NOTE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR IMMUNITY;

EID: 57049143114     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1259     Document Type: Note

References (7)

1. + T cells against NY-ESO-1. N Engl J Med 358 2698-2703
2. Dudley ME and Rosenberg SA (2007) Adoptive cell transfer therapy. Semin Oncol 34: 524-531
3. June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117: 1466-1476
4. June CH (2007) Principles of adoptive T cell cancer therapy. J Clin Invest 117: 1204-1212
5. Du J et al. (2004) Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6: 565-576
6. Rosenberg SA et al. (2008) Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308
7. Knutson KL and Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54 721-728